Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-011844.pdf
0001179110-19-011844.rtf
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-19-059813.pdf
0001104659-19-059813.rtf
0001104659-19-059813.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-Q

Quarterly report which provides a continuing view of a company's financial position

 View HTML
0001558370-19-009888.pdf
0001558370-19-009888.rtf
0001558370-19-009888.xls
EX-101.SCH - EX-101.SCH
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-011412.pdf
0001179110-19-011412.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-011290.pdf
0001179110-19-011290.rtf
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-19-009188.pdf
0001558370-19-009188.rtf
0001558370-19-009188.xls
EX-101.SCH - EX-101.SCH
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-011139.pdf
0001179110-19-011139.rtf
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-19-008914.pdf
0001558370-19-008914.rtf
0001558370-19-008914.xls
EX-101.SCH - EX-101.SCH
CT ORDER

CT ORDER

 View HTML
9999999997-19-007138.pdf
9999999997-19-007138.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-010450.pdf
0001179110-19-010450.rtf